Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 50 versus RYZOLT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 50 versus RYZOLT.
DURAGESIC-50 vs RYZOLT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
RYZOLT is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin levels in the synaptic cleft.
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
10 mg orally once daily
None Documented
None Documented
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Terminal elimination half-life is 12–15 hours in healthy adults; extended to 22–28 hours in patients with severe hepatic impairment.
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Primarily hepatic metabolism with renal excretion of metabolites; renal elimination of unchanged drug <5%; biliary excretion accounts for ~10% of total clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic